miércoles, 20 de abril de 2016

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysisDiabetes Medications as Monotherapy or Metformin-Based Combination Therapy | Annals of Internal Medicine

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysisDiabetes Medications as Monotherapy or Metformin-Based Combination Therapy | Annals of Internal Medicine

AHRQ Electronic Newsletter banner image

AHRQ Report Updates Evidence on Effectiveness of Medications for Adults With Type 2 Diabetes

A new AHRQ-funded systematic review found evidence to support current clinical guidelines identifying metformin as the recommended first-line agent to treat adults with type 2 diabetes. The conclusion is based on the medication's beneficial effects on hemoglobin A1c, weight, cardiovascular mortality (versus sulfonylureas) and relative safety profile. Researchers evaluated more than 200 studies of different diabetes drugs, more than half of which were new since AHRQ’s 2011 report on the comparative effectiveness of diabetes medicines. Diabetes affects more than 9 percent of the U.S. population. Most patients with type 2 diabetes eventually require medication to reduce long-term complications. Classes of diabetes drugs differ in their effects on glucose-lowering, safety and other important outcomes. “Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: Systematic Review and Meta-Analysis” appeared online April 19 in Annals of Internal Medicine. Read the abstract.

No hay comentarios:

Publicar un comentario